Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
13,111,117
-
Share change
-
-784,413
-
Total reported value
-
$273,902,967
-
Put/Call ratio
-
126%
-
Price per share
-
$20.91
-
Number of holders
-
93
-
Value change
-
-$16,331,751
-
Number of buys
-
46
-
Number of sells
-
37
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2022
As of 31 Mar 2022,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
93 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,111,117 shares.
The largest 10 holders included
FMR LLC, Artemis Investment Management LLP, STATE STREET CORP, BlackRock Inc., VANGUARD GROUP INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, GEODE CAPITAL MANAGEMENT, LLC, Rubric Capital Management LP, MORGAN STANLEY, and BANK OF AMERICA CORP /DE/.
This page lists
93
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.